TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02616731
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
Study: NCT02616731
Drug: Diosmin
Normalized name: Diosmin
DrugBank: Diosmin (DB08995)
Approvals — FDA: no, EMA: no, PMDA: no
Description: use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
Study: NCT01485640
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
Study: NCT02944019
Drug: Edoxaban
Normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribed according to approved label
Study: NCT01110252
Drug: Stem cells stimulation
Normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
Study: NCT02066649
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administering carvedilol to patients diagnosed with large varices on endoscopy
Study: NCT01585402
Drug: Etidronate
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
Study: NCT00120133
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00079313
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02761642
Drug: Epoetin Beta
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
Study: NCT00950651
Drug: Tramadol HCl Contramid® Once A Day
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
Study: NCT00950651
Drug: Tramadol HCl Twice a day
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
Study: NCT03768427
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
Study: NCT03768427
Drug: Placebo for atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two placebo tablets matching atorvastatin administered orally QD for 84 days
Study: NCT00467376
Drug: Insulin Glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 times a day before each meal
Study: NCT01416363
Drug: Firategrast immediate release tablet
Normalized name: Firategrast
DrugBank: Firategrast (DB12732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
Study: NCT00467376
Drug: Lispro
Normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 times a day before each meal
Study: NCT00467376
Drug: Insulin Glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: once daily
Study: NCT01440361
Drug: Belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study: NCT01440361
Drug: Normal saline placebo
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
Study: NCT00499668
Drug: aprepitant
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 125 mg orally for 7 days
Study: NCT00499668
Drug: ondansetron hydrochloride
Normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 mg orally for 7 days
Study: NCT01416363
Drug: Firategrast modified release tablet
DrugBank: Firategrast (DB12732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
Study: NCT01644643
Drug: Ceftazidime - Avibactam ( CAZ-AVI)
Normalized name: avibactam / ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
Study: NCT01644643
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
Study: NCT01416363
Drug: Firategrast gastro-retentive solution
Normalized name: Firategrast
DrugBank: Firategrast (DB12732)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
Study: NCT02756403
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg
Study: NCT00175929
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Study: NCT00175929
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
Study: NCT01999933
Drug: cisplatin（DDP） weekly
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
Study: NCT01999933
Drug: docetaxel plus cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
Study: NCT01999933
Drug: docetaxel plus cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
Study: NCT00985647
Drug: Lamivudine (3TC)
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.~3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days.
Study: NCT00881894
Drug: Rotigotine transdermal patch
Normalized name: rotigotine Transdermal System
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotigotine 4.5mg/10cm\^2 patch applied for 24 hours
Study: NCT03289533
Drug: Avelumab (MSB0010718C)
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
Study: NCT03289533
Drug: Axitinib (AG-013736)
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
Study: NCT02811822
Drug: GMI-1271
Normalized name: GMI-1070
DrugBank: Rivipansel (DB12778)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03129542
Drug: Midodrine Hydrochloride 10 milligrams
Normalized name: midodrine hydrochloride 10 MG
DrugBank: Midodrine (DB00211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three doses taken every 8 hours.
Study: NCT00363311
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dutasteride 0.5mg
Study: NCT03009461
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
Study: NCT02629861
Drug: Fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fremanezumab was provided as a sterile, unpreserved, aqueous solution for injection, 225 mg/1.5 mL pre-filled syringe for single-use administration.~The 675 mg dose was given as 3 injections; doses of 225 mg were given as a single injection. Study drug was administered at the clinical site.
Study: NCT01685684
Drug: Oxycodone DETERx
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
Study: NCT03973957
Drug: Talc Slurry
Normalized name: Talc
DrugBank: Talc (DB09511)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of 5 grams of medical grade sterile talc mixed in 50 milliliters of normal saline solution via indwelling pleural catheter for purposes of talc slurry pleurodesis
Study: NCT01485848
Drug: EP-100
Normalized name: ValcoPrep-100
DrugBank: Onvitrelin ucalontide (DB19183)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study: NCT01485848
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:Solution Route of administration: Intravenous
Study: NCT03625076
Drug: Intra-articular Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mL of 1% Lidocaine will be injected into the joint of the dislocated shoulder. Afterwards, the physician will attempt to reduce the shoulder using a technique of his or her choice.
Study: NCT03625076
Drug: Procedural Sedation with etomidate or propofol
Normalized name: Etomidate
DrugBank: Etomidate (DB00292)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procedural sedation using etomidate or propofol (physician's choice) will be performed. The dose of the drugs will also be left the treating physician. The physician will then attempt to reduce the shoulder using a technique of his or her choice.
Study: NCT04288089
Drug: Palbociclib (75, 100, 125 milligram [mg])
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib orally, once daily (QD).
Study: NCT04288089
Drug: H3B-6545 (150, 300, 450 mg)
Normalized name: H3B-8800
DrugBank: H3B-8800 (DB14017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: H3B-6545 orally, QD.
Study: NCT00707473
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00707473
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00707473
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02894398
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.~Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons
Study: NCT02894398
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
Study: NCT02894398
Drug: Anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
Study: NCT02894398
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
Study: NCT03658850
Drug: Hydrochlorothiazide 50Mg
Normalized name: HYDROCHLOROTHIAZIDE 50MG TAB
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: for the experimental group received a hydrochlorothiazide tablet on presentation of 50mg or equivalent enteral solution every 12h (total of 100mg per day) enterally on day 0 (D0) until day 3
Study: NCT00202644
Drug: Anagrelide
Normalized name: anagrelide
DrugBank: Anagrelide (DB00261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
Study: NCT02894398
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
Study: NCT04185350
Drug: 68Ga-NOTA-MAL-Cys39-exendin-4
Normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
Study: NCT04442269
Drug: dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single-use prefilled glass syringe administered by subcutaneous (SC) injection.
Study: NCT02314442
Drug: ALN-PCSSC
Normalized name: ALN-PCSsc
DrugBank: Inclisiran (DB14901)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
Study: NCT02314442
Drug: Sterile Normal Saline (0.9% NaCl)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active comparator
Study: NCT02805452
Drug: Succinate of Solifenacin
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02805452
Drug: Placebo of Succinate of Solifenacin
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00403130
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
Study: NCT00403130
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
Study: NCT00403130
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
Study: NCT00202644
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
Study: NCT03526900
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Induction (four or six 21-day cycles) : Atezolizumab 1200 mg / iv + carboplatin 5 AUCs + pemetrexed 500 mg/m2~* Maintenance (21-day cycles): atezolizumab 1200 mg/iv + pemetrexed 500 mg/m2.
Study: NCT00602576
Drug: sorafenib tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT00602576
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT01558388
Drug: Lactobacillus acidophilus
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
Study: NCT03633357
Drug: JNJ-18038683
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-18038683 has been developed by Janssen Pharmaceuticals (Johnson and Johnson), and is a relatively selective high affinity functional 5-HT7 receptor antagonist.~Participants will take two 10-mg tablets daily, for seven days.
Study: NCT03005340
Drug: Treatment C
Normalized name: Acne Treatment Cream
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol granule 10 mg
Study: NCT01474967
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
Study: NCT01474967
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
Study: NCT01850953
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is an approved smoking cessation medication.
Study: NCT02108886
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
Study: NCT02239926
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
Study: NCT02921789
Drug: Bleselumab
Normalized name: Bleselumab
DrugBank: Bleselumab (DB15253)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT02921789
Drug: Basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bolus injection
Study: NCT02921789
Drug: Mycophenolate Mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Intravenous
Study: NCT02921789
Drug: Tacrolimus Capsules
Normalized name: Tacrolimus Capsules
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Capsule
Study: NCT02921789
Drug: Methylprednisone
Normalized name: Methylprednisone
DrugBank: Methylprednisone (DB12952)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or Intravenous
Study: NCT02921789
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Tablet
Study: NCT03237806
Drug: Deep sedated
Normalized name: Deep Sea
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
Study: NCT03237806
Drug: Light sedated
Normalized name: kaolin light
DrugBank: Date (DB10632)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
Study: NCT01334554
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg three times a day.
Study: NCT00224393
Drug: Enbrel
Normalized name: Enbrel
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04099277
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02393859
Drug: Blinatumomab
Normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 μg/m\^2/day as a continuous intravenous infusion (CIVI) for 4 weeks
Study: NCT02393859
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/m\^2/day intravenous (IV) on Days 1-6
Study: NCT02393859
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 30 mg/m\^2 IV over 24 hours on Day 5